• 1
    Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004; 23: 65246534.
  • 2
    Armitage J. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10231030.
  • 3
    Gallagher C, Gregory W, Jones A, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986; 4: 14701480.
  • 4
    Horning S. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 20: 7588.
  • 5
    Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2003; 21: 515.
  • 6
    Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005; 105: 14171423.
  • 7
    Redman J, Cabanillas F, Velasquez W, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992; 10: 790794.
  • 8
    McLaughlin P, Hagemeister F, Swan FJ, et al. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994; 12: 575579.
  • 9
    Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with Stage IV indolent lymphoma. Blood. 2002; 100: 43514357.
  • 10
    Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol. 2004; 22: 26542661.
  • 11
    Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004; 22: 47114716.
  • 12
    Van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic stem cell transplantation for follicular lymphoma. Blood. 2003; 102: 35213529.
  • 13
    Cheson BD. Radioimmunotherapy of non-Hodgkin's lymphoma. Blood. 2003; 101: 391398.
  • 14
    Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 12621269.
  • 15
    Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001; 19: 39183928.
  • 16
    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2003; 20: 24532463.
  • 17
    Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004; 10: 77927798.
  • 18
    Kaminski MS, Zelenetz AD, Leonard JP, et al. Bexxar radioimmunotherapy produces a substantial number of durable complete responses in patients with multiply relapsed or refractory low grade or transformed low grade non-Hodgkin's lymphoma [abstract]. Blood. 2002; 100(Suppl, pt 1): 356a.
  • 19
    Kaminski MS, Tuck M, Estes J, et al. 131-I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352: 441449.
  • 20
    Press OW, Unger JM, Braziel RM, et al. A Phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin's lymphomas (SWOG S9911). Blood. 2003; 102: 16061612.
  • 21
    Leonard JP, Coleman M, Kostakoglu L, et al. Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) [abstract 6418]. Proc Am Soc Clin Oncol. 2004; 23: 560.
  • 22
    Coleman M, Kaminski MS, Knox SJ, et al. The Bexxar® therapeutic regimen (tositumomab and iodine I 131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed/refractory disease, and rituximab-naive disease [abstract 89]. Blood. 2003; 102(Suppl, pt 1): 29a.
  • 23
    Vose JM, Wahl RL, Saleh M, et al. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000; 18: 13161323.
  • 24
    Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005; 23: 712719.
  • 25
    Davies AJ, Rohatiner AZS, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22: 14691479.
  • 26
    Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I131 tositumomab (Bexxar). Blood. 2005; 105: 45764582.
  • 27
    Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003: 21: 12631270.
  • 28
    Ansell SM, Ristow KM, Habermann TM, et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 38853890.
  • 29
    Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003; 30(Suppl 4): 3138.